NM
ORKA

Newtyn Management’s Oruka Therapeutics ORKA Stock Holding History

Newtyn Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-22,443
Closed -$458K – 48
2023
Q4 		$458K Sell
22,443
-2,557
-10% -$57.4K 0.09% 44
2023
Q3 		$603K Sell
25,000
-1,100
-4% -$26.9K 0.15% 41
2023
Q2 		$636K Sell
26,100
-17,214
-40% -$424K 0.15% 39
2023
Q1 		$1.03M Sell
43,314
-1,543
-3% -$40.7K 0.2% 56
2022
Q4 		$1.27M Buy
44,857
+3,190
+8% +$81.8K 0.26% 48
2022
Q3 		$1.03M Buy
+41,667
New +$1.18M 0.23% 54

Other funds holding ORKA

CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $295M AUM 40.98% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Newtyn Management's ORKA Position: Q1 2024 in Review

Newtyn Management sold out of Oruka Therapeutics (ORKA) in Q1 2024, closing a stake of 22,443 shares — an estimated $458K sold.

Newtyn Management first reported a position in ORKA in Q3 2022 and held it in 6 quarters. The position peaked at $1.27M in Q4 2022. 22 funds tracked by Wall St. Rank hold ORKA as of Q1 2024.

  • Newtyn Management reported no remaining Oruka Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Newtyn Management sold 22,443 Oruka Therapeutics shares in Q1 2024, an estimated $458K.
  • Newtyn Management first reported a position in Oruka Therapeutics in Q3 2022 and held it in 6 quarters.
  • Newtyn Management's Oruka Therapeutics position peaked at $1.27M in Q4 2022.
  • 22 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2024.

Based on Newtyn Management's 13F filing for Q1 2024, filed 15 May 2024.